Echocardiographic Findings in Patients With COVID-19 Pneumonia

Hani M Mahmoud-Elsayed, William E Moody, William M Bradlow, Ayisha M Khan-Kheil, Jonathan Senior, Lucy E Hudsmith, Richard P Steeds, Hani M Mahmoud-Elsayed, William E Moody, William M Bradlow, Ayisha M Khan-Kheil, Jonathan Senior, Lucy E Hudsmith, Richard P Steeds

Abstract

The aim of this study was to characterize the echocardiographic phenotype of patients with COVID-19 pneumonia and its relation to biomarkers. Seventy-four patients (59 ± 13 years old, 78% male) admitted with COVID-19 were included after referral for transthoracic echocardiography as part of routine care. A level 1 British Society of Echocardiography transthoracic echocardiography was used to assess chamber size and function, valvular disease, and likelihood of pulmonary hypertension. The chief abnormalities were right ventricle (RV) dilatation (41%) and RV dysfunction (27%). RV impairment was associated with increased D-dimer and C-reactive protein levels. In contrast, left ventricular function was hyperdynamic or normal in most (89%) patients.

Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Relationship between biomarkers and right ventricular systolic function. Pearson correlation was used for normally distributed data, and Spearman rank correlation for data not normally distributed; a 2-tailed P < 0.05 was considered significant.

References

    1. Hindocha R., Garry D., Short N. Minimum dataset for a level 1 echocardiogram: a guideline protocol from the British Society of Echocardiography. Echo Res Prac. 2020;7 G51-8.
    1. Lang R.M., Badano L.P., Mor-Avi V. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14.
    1. Galiè N., Humbert M., Vachiery J.L. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J. 2016;37:67–119.
    1. Tang N., Bai H., Chen X. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.
    1. Paranjpe I., Fuster V., Lala A. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:122–124.
    1. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) [e-pub ahead of print]. JAMA Cardiol 10.1001/jamacardio.2020.1096.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel